NCT06222658

Brief Summary

The goal of our protocol is to re-establish patency in ALLI, by combining both balloon maceration of a thrombus and angiojet PMT thus decreasing complications associated with prolonged periods of thrombolytic exposure while avoid open surgical risk .

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 26, 2023

Completed
4 months until next milestone

Study Start

First participant enrolled

January 20, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 25, 2024

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 20, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2025

Completed
Last Updated

January 25, 2024

Status Verified

January 1, 2024

Enrollment Period

1.7 years

First QC Date

September 26, 2023

Last Update Submit

January 15, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Procedure success

    completion of the endovascular procedure without the need for further intervention for revascularization and an absence of substantial or complete occlusion in any vessel at final angiography

    immediately after angiography

  • Amputation-free survival

    freedom from amputation to the treated limb or mortality at follow-up at 30 days, 6 months and 1 year

    1 year

Study Arms (1)

Patient assigned to pharmacomechanichal thrombectomy

EXPERIMENTAL
Device: pharmaco-mechanichal thrombectomy

Interventions

pharmaco-mechanichal thrombectomy in acute limb ischemia

Also known as: Angiojet thrombectomy catheter
Patient assigned to pharmacomechanichal thrombectomy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years
  • Symptom onset within 14 days for acute limb ischemia or within 30 days for subacute limb ischemia due to embolic or thrombotic occlusion of a native arteries, bypass graft, or arterial stent.
  • Rutherford category I, IIa or IIb

You may not qualify if:

  • ALLI secondary to dissections, vasculitis, and/or target vessel trauma
  • Pregnancy or positive pregnancy test
  • Rutherford category III Irreversible (neglected) limb ischemia
  • patients allergic to contrast agent,
  • serum creatine\>300 mmol/L

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asyut University Hospital

Asyut, Egypt

RECRUITING

Related Publications (2)

  • Ascher E, Kibrik P, Rizvi SA, Alsheekh A, Marks N, Hingorani A. Fast-track thrombolysis protocol for acute limb ischemia. J Vasc Surg. 2021 Mar;73(3):950-959. doi: 10.1016/j.jvs.2020.03.061. Epub 2020 May 11.

    PMID: 32437952BACKGROUND
  • Leung DA, Blitz LR, Nelson T, Amin A, Soukas PA, Nanjundappa A, Garcia MJ, Lookstein R, Simoni EJ. Rheolytic Pharmacomechanical Thrombectomy for the Management of Acute Limb Ischemia: Results From the PEARL Registry. J Endovasc Ther. 2015 Aug;22(4):546-57. doi: 10.1177/1526602815592849. Epub 2015 Jun 24.

    PMID: 26109628BACKGROUND

Related Links

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
dr

Study Record Dates

First Submitted

September 26, 2023

First Posted

January 25, 2024

Study Start

January 20, 2024

Primary Completion

September 20, 2025

Study Completion

December 20, 2025

Last Updated

January 25, 2024

Record last verified: 2024-01

Locations